ERBB2 and breast cancer: For adjuvant therapy of human epidermal growth factor receptor 2 (HER2) positive breast cancer, combinations of docetaxel and trastuzumab (and pertuzumab) demonstrate synergistic cytotoxic activity while also being favorable from both safety and efficacy perspectives (Burris, 2001).